A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Canada

Hôpital Maisonneuve-Rosemont, Montreal, Quebec